|
|
|
|
Michael Zelefsky, M.D.
Dr. Zelefsky, a director of the company, is a nationally and internationally
recognized Radiation Oncologist who is Associate Professor of Radiation Oncology
at Memorial Sloan-Kettering Cancer Center in New York where he is also the Chief
of the Brachytherapy Service. His primary clinical focus is in the treatment
of Genitourinary Cancers including prostate and bladder cancers as well as Head
and Neck Cancers. He has been the Principal Investigator on many clinical research
studies, which have included protocols incorporating novel drugs in conjunction
with radiotherapy for the treatment of locally advanced cancers. Dr Zelefsky
has been the Principal Investigator who tested Imclone’s C225 in conjunction
with chemo-radiotherapy for advanced Head and Neck Cancer as well as the current
PI on a Phase III randomized trial supported in part by Astra Zeneca testing
the role of hormone therapy in conjunction with high-dose radiotherapy. He has
published well over 150 peer-reviewed articles, chapters and review articles.
He is the Editor in Chief of Brachytherapy, the premier journal in the country
on Brachytherapy in the management of cancer and is the Chairman of the National
Patterns of Care Study- Genitourinary Section. He has been selected as one of
the Best Doctors in New York and also chosen as one of top Doctors in the United
States in the Castle Connolly listing for 2003.
|
|
|
|
|